Cardiff Lexington Corporation reports operating and capital-market developments for a healthcare services holding company focused on orthopedic, spine and pain-management platforms. Its current revenue is derived from Nova Ortho and Spine, which operates regional specialty and ancillary orthopedic care centers in Florida and Georgia that provide diagnostic services, surgical services, primary care evaluations, interventional pain management and specialty consultations for traumatic injury patients.
Recurring updates include financial results, patient-volume and procedure mix, facility and clinician additions, activity at Nova Ortho and Spine locations, acquisition strategy for orthopedic practices and related healthcare assets, OTC market status, reverse stock split actions, registration-statement activity and board governance changes.
Cardiff Lexington (OTCQB: CDIX) subsidiary Nova Ortho and Spine expanded its Florida clinical team on February 26, 2026 by hiring two procedurally trained nurse practitioners to support rising patient volume across Orlando and southeastern Florida.
The hires—Catherine Amanda Kelly, MSN, APRN, FNP-BC, and Ashley Logan, APRN-BC—bring combined procedural, neurosurgery, orthopedic surgery and pain management experience intended to improve operational efficiency, safety and patient satisfaction.
Cardiff Lexington Corporation (OTCQB:CDIXD / intends Nasdaq: CDIX) filed a registration statement on Form S-1 on December 15, 2025 for a proposed initial public offering of common stock and announced plans to uplist to Nasdaq Capital Market under the symbol CDIX. The company has engaged R. F. Lafferty & Co., Inc. as sole bookrunning manager to advise on market strategy, capital formation, valuation, investor positioning, and regulatory readiness. The number of shares and price range are not yet determined; the offering is subject to SEC effectiveness, Nasdaq approval, and market conditions.
Cardiff Lexington (OTCQB:CDIX) announced a 1-for-3 reverse stock split effective 12:01 a.m. ET on January 12, 2026. Every three pre-split shares were combined into one post-split share; fractional shares were not issued and were rounded up to the nearest whole share. The par value remained $0.001 and unchanged. The company’s common stock will trade on a split-adjusted basis on the OTCQB today, and the ticker will temporarily change to CDIXD for 20 trading days including the effective date. The stated purpose is to support compliance with Nasdaq Capital Market minimum bid price requirements. Post-split CUSIP is 14146R700.
Cardiff Lexington (OTCQB: CDIX) announced that long-serving Chairman Daniel Thompson will retire effective December 31, 2025 after 25 years of service. Alex Cunningham, President and Chief Executive Officer, will succeed Thompson as Chairman and assume the additional role immediately upon retirement.
The release says the company is positioned for further growth, highlights expansion of its operating subsidiary Nova Ortho and Spine in 2025, and cites a targeted plan to uplist the stock to a major US exchange to broaden investor visibility.
Cardiff Lexington (OTCQB:CDIX) announced that its subsidiary Nova Ortho and Spine performed first procedures on December 11, 2025 at Doctor's Memorial Hospital in Perry, Florida.
The move targets Taylor County, described as severely underserved with poor health outcomes and a high provider-to-patient ratio; Cardiff Lexington said the visit brings pain management, orthopedic, and spine surgical services to the local community and signals intent to expand into additional rural Florida areas.
Cardiff Lexington (OTCQB: CDIX) announced on November 20, 2025 that it entered an advisory agreement with Greentree Financial Group to support its uplisting strategy and strengthen financial reporting and governance.
Greentree will assist with the company’s audit process, S-1 filing, SEC and exchange comment responses, governance initiatives, and coordination with attorneys, CPAs, and transfer agents. Management described the engagement as a step toward uplisting to a major U.S. exchange and improving public markets compliance.
Cardiff Lexington (OTCQB:CDIX) reported third quarter results for the period ended September 30, 2025, showing substantial revenue and margin improvement versus the prior-year quarter.
- Total revenue rose 125.6% to $3.1 million (3Q24 included a one-time $1.7M accounting charge).
- Gross profit increased 437.8% to $1.9 million (62.4% margin).
- Income from continuing operations improved to $643,000 (21.0% of revenue).
- Non-GAAP adjusted EBITDA for Q3 was $663,000; year-to-date adjusted EBITDA was $1.9 million.
- Cash totaled $232,000 and total assets were $27.6 million.
Cardiff Lexington (OTCQB:CDIX) will release third quarter 2025 financial and operating results for the period ended September 30, 2025 and host a conference call on Friday, November 14, 2025 at 9:00 AM ET. The results will be released prior to the call.
Participants may join by dialing (888) 506-0062 (U.S.) or (973) 528-0011 (international) and using access code 223050. The call and slide deck will be webcast at https://www.webcaster5.com/Webcast/Page/3131/53160 and via the company Investor Relations page https://investor.cardifflexington.com/overview/default.aspx. A replay will be available one hour after the call through Friday, November 28, 2025 by dialing (877) 481-4010 (U.S.) or (919) 882-2331 (international) using access code 53160.
Cardiff Lexington (OTCQB:CDIX) reported strong Q2 2025 financial results, with total revenue increasing 89.5% to $2.8 million compared to Q2 2024. The company achieved significant improvements across key metrics, including a 149.8% increase in gross profit to $1.7 million and a 482.3% rise in income from continuing operations to $610,000.
Operating through 12 Nova Ortho & Spine locations in Florida and Georgia, the company demonstrated robust operational performance with gross margins reaching 60.8%. However, net loss widened to $1.2 million, primarily due to increased interest expenses of $1.8 million related to the company's line of credit. Non-GAAP adjusted EBITDA improved to $708,000 compared to a loss of $76,000 in Q2 2024.
Cardiff Lexington (OTCQB:CDIX) has scheduled its Q2 2025 financial results conference call for Tuesday, August 26, 2025, at 9:00 am ET. The company will release its financial results for the quarter ended June 30, 2025, before the call.
Investors can join via phone by dialing (888) 506-0062 (US) or (973) 528-0011 (International) using access code 861636. The call and slide deck will be available via webcast, and a replay will be accessible until September 9, 2025.